国药股份: 国药股份关于股权分置改革持续督导保荐代表人变更的公告

Core Viewpoint - The announcement details the change in the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation, with the new representative being Mr. Lu Wenjun, who has extensive experience in investment banking [1]. Group 1: Company Announcement - China National Pharmaceutical Group Corporation has received a letter from its sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for its equity division reform [1]. - Mr. Liu Xiangsheng, the previous representative, is retiring and will be succeeded by Mr. Lu Wenjun, who will continue the supervisory duties [1]. - The board expresses gratitude for Mr. Liu's contributions during his tenure [1]. Group 2: New Representative Profile - Mr. Lu Wenjun holds a master's degree and has 16 years of experience in investment banking [1]. - He has led or participated in various IPO projects and private placements, including those for companies such as Furui Special Equipment, Dashengda, and Xianhui Technology [1]. - His experience also includes involvement in bond projects and asset restructuring for several companies, showcasing his extensive background in financial advisory [1].